Ukuhlolwa Okusha Komtholampilo Komuthi Omusha Wophenyo Wokwelapha I-Alopecia

Ngo-April 2019, i-HopeMed yenza isivumelwano selayisense esikhethekile somhlaba wonke ne-Bayer AG mayelana nokuthuthukiswa nokudayiswa kwe-anti-monoclonal antibody eqondise i-PRL receptor yokwelapha ukuqothuka kwezinwele zephethini yabesilisa nabesifazane, i-endometriosis, nezinye izifo ezingamahlalakhona nge-dysregulated prolactin. (PRL) ukusayina. Le antibody ibonise izici ezinhle kakhulu kumamodeli ezilwane okuhlanganisa amamodeli e-NHP nocwaningo lokuphepha kwabantu. Ukwelashwa kwayo kwezinkomba ezimbili eziyinhloko, i-endometriosis kanye ne-androgenetic alopecia, kokubili kuvunywe yi-US FDA ezinhlolweni zomtholampilo zeSigaba II. Uhlolo lomtholampilo lwesigaba II se-HMI-115 ku-endometriosis seluvele luqalile ukubhaliswa kwesiguli e-US ekupheleni kuka-2021. Uhlolo lwaso lomtholampilo lweSigaba II sokwelashwa kwe-androgenetic alopecia luyisizinda esiningi samazwe ngamazwe, olungahleliwe, olungaboni kabili, lwe-placebo- ucwaningo olulawulwayo, okuhlelwe ukuthi lwenziwe e-United States, e-Australia nakwamanye amazwe.

UDkt. Henri Doods, oyi-CEO ye-HopeMed, uthe “Ngiyaziqhenya kakhulu ngokuthi i-FDA iphinde yagunyaza i-IND yethu yesibili okuyigxathu elibalulekile enkampanini yethu encane. Kuyisinyathelo esibalulekile esiya kunjongo yethu yokuletha i-First-in-Class kanye nemikhiqizo ehluke kakhulu ezigulini. Kokubili i-endometriosis kanye ne-alopecia kuyizinkomba lapho iziguli zilindele ngabomvu izinketho ezintsha zokwelapha ezisebenza ngempumelelo nokuphepha. Impumelelo yokuba nezimvume ezimbili ze-IND ngesikhathi esifushane kangaka iyisikhuthazo kulo lonke iqembu. Sizibophezele kakhulu ekuqhubekeni nokuqinisa nokwandisa imisebenzi yethu ye-R&D ukuze ilethe izindlela zokwelapha ezintsha ezigulini emhlabeni jikelele.”